Aquestive Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Aquestive Therapeutics, Inc. (AQST) reported Increase (Decrease) in Accounts Receivable of $3.89 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2019-11-05
- Aquestive Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2018-09-30 was $810.00K.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2017-09-30 was -$552.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month |
|---|---|---|---|
| 2019-09-30 | $3.89M 10-Q · filed 2019-11-05 | ||
| 2018-09-30 | $810.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $1.29M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $481.00K 10-Q · filed 2018-09-04 | ||
| 2017-09-30 | -$552.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$3.75M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$3.20M 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |